Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biotherapeutic company Xencor has received a patent from the US Patent and Trademark Office for its proprietary protein design automation technology.
Subscribe to our email newsletter
The company said that this is the first issuance from a series of patent applications covering its XmAb antibody Fc engineering technology, which is comprised of a suite of thousands of selectively engineered Fc domains. Xencor added that its engineered Fc domains have been shown to improve antibody potency against tumor cells by more than 100-fold, significantly extend in vivo half-life and have been partnered with several large biotechnology and pharmaceutical companies to enhance specific clinical candidates.
Bassil Dahiyat, president and CEO of Xencor, said: “This is an important milestone for the continued implementation of our Fc technology, which will soon enter Phase I clinical testing in our lead clinical candidate, XmAb2513. Our team is actively pursuing a series of additional patents that will comprehensively cover the broad range of applications we have created with our Fc technology.”